NCT03301220: An ongoing trial by Janssen Research & Development, LLC
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03301220 |
|---|---|
| Title | A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 7, 2017 |
| Completion date | May 1, 2024 |
| Required reporting date | May 1, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 26, 2025 |
| Days late | None |